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Scientific summary
Background
It is important that the level of general anaesthesia (GA) is appropriate for the individual patient 
undergoing surgery. If anaesthesia is deeper than required to keep a patient unconscious, there might 
be increased risk of anaesthetic-related morbidity, such as postoperative nausea, vomiting and cognitive 
dysfunction. If anaesthesia is too light, patients may not be fully unconscious and could be at risk of 
intraoperative awareness. Intraoperative awareness is a relatively rare event with an incidence typically of 
around one to two patients per 1000. However, over time, awareness may cause depression, anxiety and 
post-traumatic stress disorder (PTSD).
During GA, patients are routinely monitored for signs of potential intraoperative awareness, including 
tachycardia (rapid heart rate), hypertension, sweating, lacrimation (tear production), movement/grimacing 
and tachypnoea (rapid breathing). In patients receiving inhaled GA, end-tidal (exhaled) anaesthetic gas 
concentrations may be assessed to gauge depth of anaesthesia. However, clinical observation alone may 
not be a reliable surrogate marker of depth of anaesthesia. Technologies have been developed using 
electroencephalography (EEG) to measure and interpret electrical activity in the brain to provide a measure 
of unconsciousness. Most devices comprise a module that collects raw EEG data via sensors placed on the 
patient’s forehead and then processes and analyses these using a mathematical algorithm. The output is 
then displayed numerically on a monitor for use by the anaesthetist to judge depth of unconsciousness, 
and to alter anaesthetic dose accordingly. Three such devices prioritised for this report are Bispectral Index 
(BIS), E-Entropy and Narcotrend.
Objectives
The objective of this report is to assess the clinical effectiveness and cost-effectiveness of BIS, E-Entropy 
and Narcotrend technologies to monitor the depth of anaesthesia in surgical patients undergoing GA.
Methods
Systematic review of patient outcomes
A systematic review of patient outcomes associated with depth of anaesthesia monitoring was conducted. 
A search strategy was developed and run on eight bibliographic electronic databases. Reference lists 
supplied by the device manufacturers were checked to identify potentially relevant studies. Eligibility 
criteria were applied to titles and abstracts and to full papers by two reviewers independently. Because of 
the relatively large volume of evidence for BIS, we included only trials that were supplemental to a recent 
Cochrane systematic review of BIS. Included studies were data extracted using a standard template. Risk 
of bias and markers of quality were assessed. The studies were synthesised narratively, with meta-analyses 
from the Cochrane review of BIS updated with supplemental studies where feasible and appropriate.
Systematic review of cost-effectiveness
A systematic review of the literature on the cost-effectiveness of depth of anaesthesia monitoring 
compared with standard clinical monitoring was undertaken. Included studies were evaluated for their 
quality and for generalisability to the UK. Eligibility criteria were applied to titles and abstracts and to full 
papers by two reviewers independently, and the studies were synthesised narratively.
© Queen’s Printer and Controller of HMSO 2013. This work was produced by Shepherd et al. under the terms of a commissioning contract issued by the Secretary of State 
for Health. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals 
provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be 
addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science 
Park, Southampton SO16 7NS, UK.
HEALTH TECHNOLOGY ASSESSMENT 2013 VOL. 17 NO. 34 (SCIENTIFIC SUMMARY)
iii
Economic evaluation
A decision-analytic model was developed to assess the cost-effectiveness of depth of anaesthesia 
monitoring compared with standard clinical observation. A simple decision tree was developed, which 
accounted for patients’ risk of experiencing short-term anaesthetic-related complications in addition to a 
risk of experiencing intraoperative awareness.
It was assumed that a proportion of patients who experience awareness will suffer psychological 
symptoms and that a proportion of those will develop PTSD and may seek treatment. A systematic review 
of health-related quality of life (HRQoL) in PTSD was undertaken in order to estimate the quality-of-life 
decrement to be applied as the result of any psychological symptoms arising from an awareness episode. 
The costs of depth of anaesthesia monitoring consist of the capital costs associated with acquisition of the 
monitor and recurring costs associated with sensors that are attached to the patient. Equivalent annual 
costs for each monitor were calculated for an effective equipment life of 5 years. Unit costs of anaesthetic 
drugs were derived from the British National Formulary (BNF) and supplied from an NHS Trust. The 
baseline incidence of awareness in high-risk patients was calculated from the control arms of randomised 
controlled trials (RCTs) in this group of patients. The summary values of the effectiveness of depth of 
anaesthesia monitoring were taken from our systematic review of patient outcomes.
The model evaluates costs [UK sterling (pounds) using a 2011 price base] from the perspective of the NHS 
and Personal Social Services. Outcomes in the model are expressed as quality-adjusted life-years (QALYs). 
Both costs and outcomes are discounted using a 3.5% annual discount rate, in line with current guidance.
Results
Systematic review of patient outcomes
From a total of 776 bibliographic records, 22 RCTs comparing BIS, E-Entropy and Narcotrend with 
standard clinical monitoring were included in the systematic review of patient outcomes. Fifteen trials of 
BIS, seven trials of E-Entropy and four trials of Narcotrend all compared with standard clinical monitoring. 
(Note that some trials compared more than one of the three devices to standard clinical monitoring.) Some 
of the trials reported that in the EEG arm anaesthesia doses were titrated according to device values in 
conjunction with clinical signs. In other trials the use of clinical signs alongside EEG monitoring was not 
explicit. The Cochrane review of BIS included 31 RCTs. The trials included in both reviews span the period 
between 1997 and 2011 in terms of publication date.
In many cases, the risk of bias in the trials was unclear because of limitations in reporting of 
methodological details. The trials varied in terms of their sample sizes, from as low as 20 to over 6000 
patients, but, in general, sample sizes were relatively small (e.g. fewer than 200). Fifteen of the trials in 
this systematic review and all of the trials in the Cochrane BIS review were conducted in adult patients, 
of varying mean ages. Seven of the trials in this review were conducted with children. The trials were 
generally single-centre studies conducted in a range of locations including Europe, North America 
and Asia.
Six trials were conducted with patients classified as having one or more risk factors for intraoperative 
awareness (e.g. planned cardiac surgery, pulmonary hypertension, end-stage lung disease), all of which 
evaluated BIS monitoring. The trials tended to exclude patients with significant ill health or factors that 
may interfere with EEG recordings.
Explicit intraoperative awareness was assessed in 16 of the trials, but in most of these no episodes were 
recorded. However, awareness is a relatively rare event and the trials were not statistically powered to 
detect it. The six trials of patients classified with risk factors for intraoperative awareness, all of which 
evaluated BIS, were combined in a fixed-effect meta-analysis. The overall pooled Peto’s odds ratio (OR) was 
0.45 [95% confidence interval (CI) 0.25 to 0.81] in favour of BIS.
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Caution is advised in the interpretation of this result as, overall, there was statistically significant 
heterogeneity (p = 0.009; I2 = 79%). Both the subgroup of trials, which included a trial of mixed inhaled 
and intravenous anaesthesia, and the subgroup, which included trials of total intravenous anaesthesia 
(TIVA), statistically favoured BIS monitoring. However, in the subgroup of trials that used only inhaled 
anaesthesia, the Peto’s OR was 1.79 (95% CI 0.63 to 5.11), favouring standard clinical monitoring, 
although not statistically significant.
Systematic review of cost-effectiveness
A total of 134 potentially relevant references were identified by the cost-effectiveness searches. Of these, 
one study comparing BIS with standard clinical monitoring met all of the inclusion criteria. The study 
reported cost per avoided intraoperative recall, with the incidence of recall with BIS reported as 0.04% 
compared with 0.18% for standard monitoring, resulting in a cost per avoided recall of US$4410. The 
authors of the study concluded that BIS monitoring did not appear cost-effective. However, the results and 
conclusions should be viewed with caution because of poor methodological and reporting quality.
Economic evaluation
For each technology we presented a base-case analysis for two modes of anaesthetic administration 
{TIVA and mixed anaesthesia [induction with intravenous (i.v.) anaesthesia and maintenance with inhaled 
anaesthesia or a combination of inhaled and i.v. anaesthetic]} and for two patient populations (those 
considered at high risk of intraoperative awareness and a general surgical population, at average risk of 
intraoperative awareness).
Bispectral Index compared with standard clinical monitoring
In cohorts of 10,000 patients at high risk of intraoperative awareness undergoing GA with TIVA, the 
incremental cost-effectiveness ratio (ICER) for BIS compared with standard clinical monitoring in this 
population was £22,339.
For the population of general surgical patients undergoing GA with TIVA, BIS monitoring was modelled 
as being associated with 3.8 cases (per 10,000 patients) of awareness, compared with 16 in patients 
receiving standard clinical monitoring. Given the lower baseline risk of awareness in this population, the 
QALY gain with BIS monitoring was lower (0.0003) than for high-risk patients. This resulted in a higher 
ICER (£34,565).
Deterministic sensitivity analyses indicated that the ICER was sensitive to the same input parameters as for 
the population at high risk of awareness.
The baseline estimates of awareness, late psychological symptoms (LPS) and PTSD for high-risk patients 
undergoing mixed GA were the same as for high-risk patients undergoing TIVA. However, given that the 
OR of awareness with BIS monitoring was higher in this analysis, the estimated reduction in LPS and PTSD 
was lower. The ICER for BIS compared with standard clinical monitoring in this population was £29,634.
The baseline estimates of awareness, LPS and PTSD in the population of general surgical patients 
undergoing mixed GA were the same as for TIVA. Although a proportion of the higher cost associated 
with BIS monitoring was offset by reduction in anaesthetic consumption, the cost-saving for inhaled 
anaesthesia was lower than for TIVA. As a result the incremental cost was greater. Given the lower baseline 
risk of awareness in this population, the QALY gain with BIS monitoring was lower (0.0003) than for high-
risk patients, resulting in a higher ICER (£49,198).
Deterministic sensitivity analyses indicated that the ICER was sensitive to a number of parameters, 
including the baseline incidence of awareness and the effectiveness of BIS in reducing awareness.
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E-Entropy compared with standard clinical monitoring
In patients at high risk of awareness undergoing GA with TIVA, the modelled cost per patient with 
E-Entropy monitoring was higher than with standard clinical monitoring, although some of the additional 
cost was offset by reduced cost associated with psychological sequelae of awareness. The ICER for 
E-Entropy compared with standard clinical monitoring in this population was £14,421.
In the population of general surgical patients undergoing GA with TIVA, E-Entropy monitoring had a 
higher cost per patient than standard clinical monitoring. There was no reduction in anaesthetic drug 
costs to offset the additional costs of E-Entropy monitoring. Given the lower baseline risk of awareness 
in this population, the QALY gain was lower than for high-risk patients, which resulted in a higher ICER 
(£31,131–31,430).
In patients considered at high risk of awareness undergoing mixed GA, E-Entropy monitoring had higher 
costs and improved outcomes compared with standard clinical monitoring. However, the QALY gain 
was lower than for patients undergoing TIVA. The ICER for E-Entropy compared with standard clinical 
monitoring in this population was £19,367.
In the population of general surgical patients undergoing mixed GA, E-Entropy monitoring had higher 
costs than standard clinical monitoring. In contrast with the analysis for TIVA, the clinical trial used to 
estimate inhaled anaesthetic drug consumption reported a substantial decrease (29%), which resulted 
in approximately half of the additional cost of E-Entropy monitoring being offset by a reduction in 
anaesthetic drug costs. Despite the lower baseline risk of awareness, which resulted in a lower QALY gain 
with E-Entropy monitoring than for high-risk patients, the lower incremental cost resulted in an equivalent 
ICER (£19,000).
Deterministic sensitivity analyses indicated that the ICER was sensitive to a number of parameters, 
including the baseline incidence of awareness and the effectiveness of E-Entropy in reducing awareness.
Narcotrend compared with standard clinical monitoring
In patients at high risk of awareness undergoing GA with TIVA, the modelled cost per patient with 
Narcotrend monitoring was higher than with standard clinical monitoring, although some of the 
additional cost was offset by reduced cost associated with psychological sequelae of awareness. The ICER 
for Narcotrend compared with standard clinical monitoring in this population was £5681. Deterministic 
sensitivity analyses indicated that the ICER was sensitive to a number of parameters, including the baseline 
incidence of awareness and the effectiveness in reducing awareness.
In the general surgical population undergoing GA with TIVA, and also undergoing mixed GA, Narcotrend 
monitoring had a lower cost per patient than standard clinical monitoring. The additional cost of 
monitoring was more than offset by reduction in anaesthetic drug consumption. Given the lower baseline 
risk of awareness in this population, the QALY gain was lower than for high-risk patients. Narcotrend 
dominated standard clinical monitoring. Narcotrend remained dominant in the majority of deterministic 
sensitivity analyses.
In patients at high risk of awareness undergoing mixed GA, Narcotrend monitoring had higher costs and 
improved outcomes than standard clinical monitoring, although the QALY gain (0.0005) was lower than 
for patients undergoing TIVA. The ICER for Narcotrend compared with standard clinical monitoring in this 
population was £8033. Deterministic sensitivity analyses indicated that the ICER was sensitive to the same 
parameters as for high-risk patients undergoing TIVA.
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Conclusions
In general, BIS, E-Entropy and Narcotrend technologies for monitoring the depth of anaesthesia are 
associated with reductions in general anaesthetic consumption, and decreased anaesthetic recovery 
times, compared with monitoring of clinical signs alone. However, these reductions may be considered 
clinically modest. The available evidence on the impact of the technologies on reducing the likelihood of 
intraoperative awareness is limited. Overall, BIS was associated with a statistically significant reduction 
in intraoperative awareness in patients classified as at higher risk, although there is uncertainty in effect 
estimates because of significant heterogeneity. Caution is advised because of uncertainties about the risk of 
bias of many of the included trials, and because many outcome measures were not statistically powered.
The cost-effectiveness of depth of anaesthesia monitoring appears to be highly dependent on the 
incidence of awareness, the HRQoL impact of psychological sequelae of awareness and the probability of 
developing psychological illness following awareness, as well as the effectiveness of depth of anaesthesia 
monitoring in reducing awareness. Cost-savings resulting from reduced use of anaesthetic drugs may 
offset some of the additional cost of depth of anaesthesia monitoring. The cost of sensors attached to the 
patient appears to be a key factor in the additional cost of depth of anaesthesia monitoring.
This report makes the following research recommendations (in priority order):
1. RCTs of E-Entropy- and Narcotrend-guided anaesthesia monitoring are needed, in high-risk patients, 
with adequate statistical power to detect explicit intraoperative awareness, and of sufficient length of 
follow-up to detect delayed cases of awareness.
2. RCTs of all three technologies should also evaluate the effects of anaesthesia overdosing, including 
short-term effects, such as nausea and vomiting, as well as longer-term impact on cognitive function.
3. RCTs of E-Entropy- and Narcotrend-guided anaesthesia monitoring are also needed in children.
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